Small cell lung cancer

Gary R. Goodman, Robert B Livingston

Research output: Contribution to journalArticle

Abstract

Lung cancer is the most common cause of cancer death in the United States, with approximately 135,000 men and women dying each year. While much has been learned about the etiologic risk factors, less progress has been made in therapy. Five-year survival rates remain at <10%. However, there has been some progress in the therapy of one histological subtype of lung cancer, small cell lung cancer. Totaling around 20% of lung cancer cases, small cell lung cancer is distinct from the other histologic subtypes in its biologic behavior and responsiveness to therapy. In the 1960s, the median survival for patients with small cell lung cancer was approximately 3 months. With combination chemotherapy and radiotherapy median survivals now range from 1 to 2 years, and there is evidence for a curative potential since approximately 10% of patients who initially present with limited disease survive >2 years. The unique clinical aspects of this histological subtype potentially relate to its underlying cell of origin. This behavior is reflected in the numerous paraneoplastic syndromes that frequently accompany small cell lung cancer. Its propensity for early dissemination have made staging the extent of disease an important part of the clinical evaluation. Since small cell lung cancer is sensitive to both chemotherapy and radiation therapy, there have been multiple clinical trials evaluating drug/radiotherapy combinations. This article will briefly describe the unique aspects of small cell lung cancer as opposed to other histological subtypes of lung cancer and give an overview of the current clinical approach and treatment of this disease.

Original languageEnglish (US)
Pages (from-to)774-825
Number of pages52
JournalDisease-a-month : DM
Volume35
Issue number12
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
Paraneoplastic Syndromes
Drug Combinations
Cause of Death
Survival Rate
Clinical Trials
Drug Therapy
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Small cell lung cancer. / Goodman, Gary R.; Livingston, Robert B.

In: Disease-a-month : DM, Vol. 35, No. 12, 1989, p. 774-825.

Research output: Contribution to journalArticle

Goodman, Gary R. ; Livingston, Robert B. / Small cell lung cancer. In: Disease-a-month : DM. 1989 ; Vol. 35, No. 12. pp. 774-825.
@article{05aaef233dac470f8a500c8af9b1c86d,
title = "Small cell lung cancer",
abstract = "Lung cancer is the most common cause of cancer death in the United States, with approximately 135,000 men and women dying each year. While much has been learned about the etiologic risk factors, less progress has been made in therapy. Five-year survival rates remain at <10{\%}. However, there has been some progress in the therapy of one histological subtype of lung cancer, small cell lung cancer. Totaling around 20{\%} of lung cancer cases, small cell lung cancer is distinct from the other histologic subtypes in its biologic behavior and responsiveness to therapy. In the 1960s, the median survival for patients with small cell lung cancer was approximately 3 months. With combination chemotherapy and radiotherapy median survivals now range from 1 to 2 years, and there is evidence for a curative potential since approximately 10{\%} of patients who initially present with limited disease survive >2 years. The unique clinical aspects of this histological subtype potentially relate to its underlying cell of origin. This behavior is reflected in the numerous paraneoplastic syndromes that frequently accompany small cell lung cancer. Its propensity for early dissemination have made staging the extent of disease an important part of the clinical evaluation. Since small cell lung cancer is sensitive to both chemotherapy and radiation therapy, there have been multiple clinical trials evaluating drug/radiotherapy combinations. This article will briefly describe the unique aspects of small cell lung cancer as opposed to other histological subtypes of lung cancer and give an overview of the current clinical approach and treatment of this disease.",
author = "Goodman, {Gary R.} and Livingston, {Robert B}",
year = "1989",
doi = "10.1016/0011-5029(89)90023-0",
language = "English (US)",
volume = "35",
pages = "774--825",
journal = "Disease-a-Month",
issn = "0011-5029",
publisher = "Mosby Inc.",
number = "12",

}

TY - JOUR

T1 - Small cell lung cancer

AU - Goodman, Gary R.

AU - Livingston, Robert B

PY - 1989

Y1 - 1989

N2 - Lung cancer is the most common cause of cancer death in the United States, with approximately 135,000 men and women dying each year. While much has been learned about the etiologic risk factors, less progress has been made in therapy. Five-year survival rates remain at <10%. However, there has been some progress in the therapy of one histological subtype of lung cancer, small cell lung cancer. Totaling around 20% of lung cancer cases, small cell lung cancer is distinct from the other histologic subtypes in its biologic behavior and responsiveness to therapy. In the 1960s, the median survival for patients with small cell lung cancer was approximately 3 months. With combination chemotherapy and radiotherapy median survivals now range from 1 to 2 years, and there is evidence for a curative potential since approximately 10% of patients who initially present with limited disease survive >2 years. The unique clinical aspects of this histological subtype potentially relate to its underlying cell of origin. This behavior is reflected in the numerous paraneoplastic syndromes that frequently accompany small cell lung cancer. Its propensity for early dissemination have made staging the extent of disease an important part of the clinical evaluation. Since small cell lung cancer is sensitive to both chemotherapy and radiation therapy, there have been multiple clinical trials evaluating drug/radiotherapy combinations. This article will briefly describe the unique aspects of small cell lung cancer as opposed to other histological subtypes of lung cancer and give an overview of the current clinical approach and treatment of this disease.

AB - Lung cancer is the most common cause of cancer death in the United States, with approximately 135,000 men and women dying each year. While much has been learned about the etiologic risk factors, less progress has been made in therapy. Five-year survival rates remain at <10%. However, there has been some progress in the therapy of one histological subtype of lung cancer, small cell lung cancer. Totaling around 20% of lung cancer cases, small cell lung cancer is distinct from the other histologic subtypes in its biologic behavior and responsiveness to therapy. In the 1960s, the median survival for patients with small cell lung cancer was approximately 3 months. With combination chemotherapy and radiotherapy median survivals now range from 1 to 2 years, and there is evidence for a curative potential since approximately 10% of patients who initially present with limited disease survive >2 years. The unique clinical aspects of this histological subtype potentially relate to its underlying cell of origin. This behavior is reflected in the numerous paraneoplastic syndromes that frequently accompany small cell lung cancer. Its propensity for early dissemination have made staging the extent of disease an important part of the clinical evaluation. Since small cell lung cancer is sensitive to both chemotherapy and radiation therapy, there have been multiple clinical trials evaluating drug/radiotherapy combinations. This article will briefly describe the unique aspects of small cell lung cancer as opposed to other histological subtypes of lung cancer and give an overview of the current clinical approach and treatment of this disease.

UR - http://www.scopus.com/inward/record.url?scp=45249130828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45249130828&partnerID=8YFLogxK

U2 - 10.1016/0011-5029(89)90023-0

DO - 10.1016/0011-5029(89)90023-0

M3 - Article

C2 - 2556255

AN - SCOPUS:45249130828

VL - 35

SP - 774

EP - 825

JO - Disease-a-Month

JF - Disease-a-Month

SN - 0011-5029

IS - 12

ER -